Current status of PET in breast cancer imaging, staging, and therapy

Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

The exact roles of PET in the imaging management of patients with known or suspected breast cancer are still in evolution. For assessing primary lesions, it is sometimes possible with PET to detect cancers occult on standard methods. This could be useful in high-risk patient populations, bur in dense breasts, background FDG uptake is often higher than in women with fatty breasts, making identification of lesions 18F- are exquisitely sensitive for metastases, and FDG is also very good. However, FDG PET can miss some blastic metastases to bone so at present FDG is not capable of excluding the presence of bone metastases. PET seems very well suited to detecting recurrences in soft tissues and the brachial plexus region in particular. The utility of PET in planning the treatment of individual patients appears promising. Although results must be confirmed in larger studies, it appears safe to conclude that failure of a chemotherapy regimen to decrease FDG uptake promptly in a breast cancer portends poor response. This does not hold true for hormonal therapy. At present, labeled estrogens are not widely available and cannot be recommended for clinical use. Thus, PET has shown considerable promise in breast cancer imaging, bur in the author's experience is best applied to solve difficult imaging questions in specific patients and is not recommended for routine evaluation of the breast cancer patient. However, in larger primary tumors, the ability to use PET for staging and to plan treatment response suggest it will be more widely used. Additional studies with newer PET imaging devices and FDG and other tracers will help us better determine the role of PET in routine clinical care of the patient with known or suspected breast cancer. Certainly, this represent a fertile area for translational research studies over the next several years with the potential to significantly alter the way breast cancer is imaged and managed.

Original languageEnglish (US)
Pages (from-to)250-260
Number of pages11
JournalSeminars in Roentgenology
Volume36
Issue number3
StatePublished - 2001

Fingerprint

Neoplasm Staging
Breast Neoplasms
Neoplasm Metastasis
Breast
Therapeutics
Bone and Bones
Translational Medical Research
Brachial Plexus
Neoplasms
Patient Care
Estrogens
Recurrence
Drug Therapy
Equipment and Supplies
Population

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Current status of PET in breast cancer imaging, staging, and therapy. / Wahl, Richard L.

In: Seminars in Roentgenology, Vol. 36, No. 3, 2001, p. 250-260.

Research output: Contribution to journalArticle

Wahl, Richard L. / Current status of PET in breast cancer imaging, staging, and therapy. In: Seminars in Roentgenology. 2001 ; Vol. 36, No. 3. pp. 250-260.
@article{02a95af5e92a4a8c9dd8ce684ba4d493,
title = "Current status of PET in breast cancer imaging, staging, and therapy",
abstract = "The exact roles of PET in the imaging management of patients with known or suspected breast cancer are still in evolution. For assessing primary lesions, it is sometimes possible with PET to detect cancers occult on standard methods. This could be useful in high-risk patient populations, bur in dense breasts, background FDG uptake is often higher than in women with fatty breasts, making identification of lesions 18F- are exquisitely sensitive for metastases, and FDG is also very good. However, FDG PET can miss some blastic metastases to bone so at present FDG is not capable of excluding the presence of bone metastases. PET seems very well suited to detecting recurrences in soft tissues and the brachial plexus region in particular. The utility of PET in planning the treatment of individual patients appears promising. Although results must be confirmed in larger studies, it appears safe to conclude that failure of a chemotherapy regimen to decrease FDG uptake promptly in a breast cancer portends poor response. This does not hold true for hormonal therapy. At present, labeled estrogens are not widely available and cannot be recommended for clinical use. Thus, PET has shown considerable promise in breast cancer imaging, bur in the author's experience is best applied to solve difficult imaging questions in specific patients and is not recommended for routine evaluation of the breast cancer patient. However, in larger primary tumors, the ability to use PET for staging and to plan treatment response suggest it will be more widely used. Additional studies with newer PET imaging devices and FDG and other tracers will help us better determine the role of PET in routine clinical care of the patient with known or suspected breast cancer. Certainly, this represent a fertile area for translational research studies over the next several years with the potential to significantly alter the way breast cancer is imaged and managed.",
author = "Wahl, {Richard L.}",
year = "2001",
language = "English (US)",
volume = "36",
pages = "250--260",
journal = "Seminars in Roentgenology",
issn = "0037-198X",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Current status of PET in breast cancer imaging, staging, and therapy

AU - Wahl, Richard L.

PY - 2001

Y1 - 2001

N2 - The exact roles of PET in the imaging management of patients with known or suspected breast cancer are still in evolution. For assessing primary lesions, it is sometimes possible with PET to detect cancers occult on standard methods. This could be useful in high-risk patient populations, bur in dense breasts, background FDG uptake is often higher than in women with fatty breasts, making identification of lesions 18F- are exquisitely sensitive for metastases, and FDG is also very good. However, FDG PET can miss some blastic metastases to bone so at present FDG is not capable of excluding the presence of bone metastases. PET seems very well suited to detecting recurrences in soft tissues and the brachial plexus region in particular. The utility of PET in planning the treatment of individual patients appears promising. Although results must be confirmed in larger studies, it appears safe to conclude that failure of a chemotherapy regimen to decrease FDG uptake promptly in a breast cancer portends poor response. This does not hold true for hormonal therapy. At present, labeled estrogens are not widely available and cannot be recommended for clinical use. Thus, PET has shown considerable promise in breast cancer imaging, bur in the author's experience is best applied to solve difficult imaging questions in specific patients and is not recommended for routine evaluation of the breast cancer patient. However, in larger primary tumors, the ability to use PET for staging and to plan treatment response suggest it will be more widely used. Additional studies with newer PET imaging devices and FDG and other tracers will help us better determine the role of PET in routine clinical care of the patient with known or suspected breast cancer. Certainly, this represent a fertile area for translational research studies over the next several years with the potential to significantly alter the way breast cancer is imaged and managed.

AB - The exact roles of PET in the imaging management of patients with known or suspected breast cancer are still in evolution. For assessing primary lesions, it is sometimes possible with PET to detect cancers occult on standard methods. This could be useful in high-risk patient populations, bur in dense breasts, background FDG uptake is often higher than in women with fatty breasts, making identification of lesions 18F- are exquisitely sensitive for metastases, and FDG is also very good. However, FDG PET can miss some blastic metastases to bone so at present FDG is not capable of excluding the presence of bone metastases. PET seems very well suited to detecting recurrences in soft tissues and the brachial plexus region in particular. The utility of PET in planning the treatment of individual patients appears promising. Although results must be confirmed in larger studies, it appears safe to conclude that failure of a chemotherapy regimen to decrease FDG uptake promptly in a breast cancer portends poor response. This does not hold true for hormonal therapy. At present, labeled estrogens are not widely available and cannot be recommended for clinical use. Thus, PET has shown considerable promise in breast cancer imaging, bur in the author's experience is best applied to solve difficult imaging questions in specific patients and is not recommended for routine evaluation of the breast cancer patient. However, in larger primary tumors, the ability to use PET for staging and to plan treatment response suggest it will be more widely used. Additional studies with newer PET imaging devices and FDG and other tracers will help us better determine the role of PET in routine clinical care of the patient with known or suspected breast cancer. Certainly, this represent a fertile area for translational research studies over the next several years with the potential to significantly alter the way breast cancer is imaged and managed.

UR - http://www.scopus.com/inward/record.url?scp=0034926124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034926124&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 250

EP - 260

JO - Seminars in Roentgenology

JF - Seminars in Roentgenology

SN - 0037-198X

IS - 3

ER -